Organogenesis Financial Statements From 2010 to 2026

ORGO Stock  USD 4.54  0.10  2.16%   
Organogenesis Holdings' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Organogenesis Holdings' valuation are provided below:
Gross Profit
346.6 M
Profit Margin
0.0022
Market Capitalization
588.2 M
Enterprise Value Revenue
1.4983
Revenue
465.2 M
We have found one hundred twenty available trending fundamental ratios for Organogenesis Holdings, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to check out Organogenesis Holdings' recent fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 5th of January 2026, Market Cap is likely to grow to about 699.2 M. Also, Enterprise Value is likely to grow to about 704.9 M

Organogenesis Holdings Total Revenue

582.07 Million

Check Organogenesis Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Organogenesis Holdings' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 1.7 M or Selling General Administrative of 355.6 M, as well as many indicators such as Price To Sales Ratio of 0.95, Dividend Yield of 0.0034 or PTB Ratio of 1.19. Organogenesis financial statements analysis is a perfect complement when working with Organogenesis Holdings Valuation or Volatility modules.
  
Build AI portfolio with Organogenesis Stock
Check out the analysis of Organogenesis Holdings Correlation against competitors.
To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.

Organogenesis Holdings Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets315.2 M572.6 M237.8 M
Slightly volatile
Total Current Liabilities51.6 M89.1 M38.7 M
Slightly volatile
Other Liabilities1.2 M1.3 M3.8 M
Very volatile
Accounts Payable24.6 M33.2 M20 M
Slightly volatile
Cash163.7 M155.9 M55.5 M
Slightly volatile
Other Assets1.091.154.2 M
Pretty Stable
Long Term Debt65.7 M69.9 M64.8 M
Pretty Stable
Net Receivables132.7 M126.3 M52.7 M
Slightly volatile
Short Term Investments146.2 K173.7 K149.9 K
Slightly volatile
Inventory21.6 M30.2 M18.6 M
Slightly volatile
Other Current Assets17.3 M16.4 M4.9 M
Slightly volatile
Total Liabilities114.1 M129.5 M81.5 M
Slightly volatile
Total Current Assets345.3 M328.8 M118.2 M
Slightly volatile
Common Stock11.1 K11.7 K34.6 M
Pretty Stable
Property Plant Equipment123.7 M117.8 M64.2 M
Slightly volatile
Short and Long Term Debt Total83.3 M49.8 M49 M
Slightly volatile
Non Current Assets Total199.8 M243.7 M133 M
Slightly volatile
Cash And Short Term Investments163.7 M155.9 M55.5 M
Slightly volatile
Common Stock Shares Outstanding103.3 M151.4 M88.8 M
Slightly volatile
Liabilities And Stockholders Equity346.5 M572.6 M239.5 M
Slightly volatile
Non Current Liabilities Total68.3 M40.4 M43 M
Slightly volatile
Capital Surpluse182.7 M357.6 M146.5 M
Slightly volatile
Non Current Liabilities Other764.4 K804.6 K145.5 M
Slightly volatile
Net Invested Capital275.1 M302.3 M274.4 M
Very volatile
Property Plant And Equipment Net109.9 M145.2 M74.8 M
Slightly volatile
Current Deferred Revenue30.6 M41.1 M31.4 M
Slightly volatile
Long Term Debt Total76.6 M76.2 M60.4 M
Slightly volatile
Capital Lease Obligations40.6 M49.8 M28.8 M
Slightly volatile
Property Plant And Equipment Gross133.5 M229.1 M89.9 M
Slightly volatile
Capital Stock147.8 M140.8 M24.2 M
Slightly volatile

Organogenesis Holdings Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative355.6 M338.7 M137.9 M
Slightly volatile
Research Development60.7 M57.8 M21.5 M
Slightly volatile
Cost Of Revenue72.6 M133.1 M65.7 M
Slightly volatile
Total Operating Expenses223 M422.7 M198.5 M
Slightly volatile
Interest Income10.9 M10.3 M5.6 M
Slightly volatile
Reconciled Depreciation15.2 M19.6 M11 M
Slightly volatile
Selling And Marketing Expenses4.3 MM2.6 M
Slightly volatile

Organogenesis Holdings Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation11.3 M19.6 M10.3 M
Slightly volatile
Capital Expenditures13.1 M11.5 M9.2 M
Slightly volatile
End Period Cash Flow164.4 M156.6 M56.1 M
Slightly volatile
Stock Based Compensation12.8 M12.2 M3.7 M
Slightly volatile
Begin Period Cash Flow126 M120 M43.8 M
Slightly volatile
Cash Flows Other Operating14.6 M19.6 M8.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.951.012.5918
Slightly volatile
Dividend Yield0.00340.00380.0042
Slightly volatile
PTB Ratio1.191.262.6118
Pretty Stable
Days Sales Outstanding53.6774.8765.4436
Pretty Stable
Book Value Per Share6.273.3715.9278
Slightly volatile
Stock Based Compensation To Revenue0.02070.01970.0097
Slightly volatile
Capex To Depreciation0.780.530.6744
Slightly volatile
PB Ratio1.191.262.6118
Pretty Stable
EV To Sales0.750.792.676
Slightly volatile
Inventory Turnover4.55.084.6769
Slightly volatile
Days Of Inventory On Hand10195.0982.59
Slightly volatile
Payables Turnover2.493.61.9193
Slightly volatile
Sales General And Administrative To Revenue0.680.70.7028
Slightly volatile
Research And Ddevelopement To Revenue0.06080.09390.0665
Slightly volatile
Capex To Revenue0.0360.01870.0263
Slightly volatile
Cash Per Share0.480.930.4412
Slightly volatile
Payout Ratio1.671.882.0514
Slightly volatile
Days Payables Outstanding99.61105768
Slightly volatile
Income Quality15.5914.853.711
Slightly volatile
Intangibles To Total Assets0.180.09530.2317
Slightly volatile
Current Ratio1.73.321.6373
Slightly volatile
Receivables Turnover6.075.055.5991
Slightly volatile
Graham Number0.720.752.0784
Slightly volatile
Shareholders Equity Per Share6.263.3715.9249
Slightly volatile
Capex Per Share0.110.06860.1402
Pretty Stable
Revenue Per Share2.613.293.01
Slightly volatile
Interest Debt Per Share0.290.310.6899
Very volatile
Debt To Assets0.0950.10.2791
Slightly volatile
Operating Cycle127149145
Slightly volatile
Price Book Value Ratio1.191.262.6118
Pretty Stable
Days Of Payables Outstanding99.61105768
Slightly volatile
Dividend Payout Ratio1.671.882.0514
Slightly volatile
Ebt Per Ebit2.071.970.925
Slightly volatile
Long Term Debt To Capitalization0.08910.09370.3426
Slightly volatile
Total Debt To Capitalization0.110.120.5226
Slightly volatile
Quick Ratio1.523.021.473
Slightly volatile
Cash Ratio0.871.570.8714
Slightly volatile
Days Of Inventory Outstanding10195.0982.59
Slightly volatile
Days Of Sales Outstanding53.6774.8765.4436
Pretty Stable
Price To Book Ratio1.191.262.6118
Pretty Stable
Fixed Asset Turnover4.624.394.5556
Slightly volatile
Debt Ratio0.0950.10.2791
Slightly volatile
Price Sales Ratio0.951.012.5918
Slightly volatile
Asset Turnover1.181.111.131
Slightly volatile
Gross Profit Margin0.580.680.6792
Slightly volatile
Price Fair Value1.191.262.6118
Pretty Stable

Organogenesis Holdings Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap699.2 M484.6 M629.7 M
Pretty Stable
Enterprise Value704.9 M378.5 M626.2 M
Pretty Stable

Organogenesis Fundamental Market Drivers

Forward Price Earnings12.3153
Cash And Short Term Investments135.6 M

Organogenesis Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Organogenesis Holdings Financial Statements

Organogenesis Holdings investors utilize fundamental indicators, such as revenue or net income, to predict how Organogenesis Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue41.1 M30.6 M
Total Revenue554.3 M582.1 M
Cost Of Revenue133.1 M72.6 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.70  0.68 
Research And Ddevelopement To Revenue 0.09  0.06 
Capex To Revenue 0.02  0.04 
Revenue Per Share 3.29  2.61 

Pair Trading with Organogenesis Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organogenesis Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organogenesis Holdings will appreciate offsetting losses from the drop in the long position's value.

Moving together with Organogenesis Stock

  0.8AMGN Amgen IncPairCorr

Moving against Organogenesis Stock

  0.72HPQ HP IncPairCorr
  0.62HD Home DepotPairCorr
  0.52MSFT MicrosoftPairCorr
  0.34PG Procter GamblePairCorr
The ability to find closely correlated positions to Organogenesis Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organogenesis Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organogenesis Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organogenesis Holdings to buy it.
The correlation of Organogenesis Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organogenesis Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organogenesis Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Organogenesis Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Organogenesis Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organogenesis Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organogenesis Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organogenesis Holdings Stock:
Check out the analysis of Organogenesis Holdings Correlation against competitors.
To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.222
Earnings Share
(0.08)
Revenue Per Share
3.651
Quarterly Revenue Growth
0.31
Return On Assets
0.0018
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.